Glickman Urological & Kidney Institute Outcomes
Surgical Quality Improvement
Transurethral Resection of the Prostate (TURP) Outcomes
January 1, 2023 – December 31, 2023
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s transurethral resection of the prostate (TURP) ACS NSQIP performance benchmarked against 458 participating sites.
| Transurethral Resection of the Prostate (TURP) (458 sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Morbidity | 89 | 3.37% | 4.86% |
| Cardiac | 89 | 0.00% | 0.15% |
| Unplanned Intubation | 89 | 1.12% | 0.09% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 89 | 0.00% | 0.20% |
| Renal Failure | 89 | 1.12% | 0.19% |
| Urinary Tract Infection (UTI) | 89 | 2.25% | 3.90% |
| Surgical Site Infection (SSI) | 89 | 0.00% | 0.24% |
| Sepsis | 89 | 2.25% | 0.80% |
| Unplanned Reoperation | 89 | 1.12% | 1.58% |
| Unplanned Readmission | 89 | 6.74% | 4.80% |
American College of Surgeons National Surgical Quality Improvement Program, 2024.
ACS NSQIP® Semiannual Report July 8, 2024, Chicago: American College of Surgeons.
